Tipifarnib in Recurrent, Metastatic HRAS-Mutant Salivary Gland Cancer

BACKGROUND: To the authors’ knowledge, there are no approved therapies for recurrent, metastatic (R/M) salivary gland carcinoma (SGC), but molecularly targeted therapies warrant ongoing investigation. In the current study, the authors have reported on the efficacy of tipifarnib in patients with aggr...

Full description

Saved in:
Bibliographic Details
Published in:Cancer
Main Authors: Hanna, Glenn J., Guenette, Jeffrey P., Chau, Nicole G., Sayehli, Cyrus M., Wilhelm, Christian, Metcalf, Robert, Wong, Deborah J., Brose, Marcia, Razaq, Mohammad, Pérez-Ruiz, Elisabeth, Cohen, Ezra E. W., Aggarwal, Rahul, Scholz, Catherine, Gualberto, Antonio, Ho, Alan L.
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8266417/
https://ncbi.nlm.nih.gov/pubmed/32557577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33036
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items